Skip to main content
NCBI home page
Emerging Infectious Diseases logoLink to Emerging Infectious Diseases
. 2001 Mar-Apr;7(2):286–292. doi: 10.3201/eid0702.010228

Economic impact of antimicrobial resistance.

J E McGowan Jr 1
PMCID: PMC2631707  PMID: 11294725

Abstract

One reason antimicrobial-drug resistance is of concern is its economic impact on physicians, patients, health-care administrators, pharmaceutical producers, and the public. Measurement of cost and economic impact of programs to minimize antimicrobial-drug resistance is imprecise and incomplete. Studies to describe and evaluate the problem will have to employ new methods and be of large scale to produce information that is broadly applicable.

Full Text

The Full Text of this article is available as a PDF (66.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abramson M. A., Sexton D. J. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? Infect Control Hosp Epidemiol. 1999 Jun;20(6):408–411. doi: 10.1086/501641. [DOI] [PubMed] [Google Scholar]
  2. Austin D. J., Kristinsson K. G., Anderson R. M. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc Natl Acad Sci U S A. 1999 Feb 2;96(3):1152–1156. doi: 10.1073/pnas.96.3.1152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bhavnani S. M., Drake J. A., Forrest A., Deinhart J. A., Jones R. N., Biedenbach D. J., Ballow C. H. A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis. 2000 Mar;36(3):145–158. doi: 10.1016/s0732-8893(99)00136-4. [DOI] [PubMed] [Google Scholar]
  4. Bryce E. A., Tiffin S. M., Isaac-Renton J. L., Wright C. J. Evidence of delays in transferring patients with methicillin-resistant Staphylococcus aureus or vancomycin-resistant Enterococcus to long-term-care facilities. Infect Control Hosp Epidemiol. 2000 Apr;21(4):270–271. doi: 10.1086/501757. [DOI] [PubMed] [Google Scholar]
  5. Burke J. P. Antibiotic resistance--squeezing the balloon? JAMA. 1998 Oct 14;280(14):1270–1271. doi: 10.1001/jama.280.14.1270. [DOI] [PubMed] [Google Scholar]
  6. Carmeli Y., Troillet N., Karchmer A. W., Samore M. H. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med. 1999 May 24;159(10):1127–1132. doi: 10.1001/archinte.159.10.1127. [DOI] [PubMed] [Google Scholar]
  7. Chrischilles E. A., Scholz D. A. Dollars and sense: a practical guide to cost analysis for hospital epidemiology and infection control. Clin Perform Qual Health Care. 1999 Apr-Jun;7(2):107–111. [PubMed] [Google Scholar]
  8. Coast J., Smith R. D., Millar M. R. An economic perspective on policy to reduce antimicrobial resistance. Soc Sci Med. 1998 Jan;46(1):29–38. doi: 10.1016/s0277-9536(97)00132-9. [DOI] [PubMed] [Google Scholar]
  9. Coast J., Smith R. D., Millar M. R. Superbugs: should antimicrobial resistance be included as a cost in economic evaluation? Health Econ. 1996 May-Jun;5(3):217–226. doi: 10.1002/(SICI)1099-1050(199605)5:3<217::AID-HEC200>3.0.CO;2-S. [DOI] [PubMed] [Google Scholar]
  10. Cohen M. L. Epidemiology of drug resistance: implications for a post-antimicrobial era. Science. 1992 Aug 21;257(5073):1050–1055. doi: 10.1126/science.257.5073.1050. [DOI] [PubMed] [Google Scholar]
  11. Dagan R., Givon-Lavi N., Shkolnik L., Yagupsky P., Fraser D. Acute otitis media caused by antibiotic-resistant Streptococcus pneumoniae in southern Israel: implication for immunizing with conjugate vaccines. J Infect Dis. 2000 Apr 7;181(4):1322–1329. doi: 10.1086/315383. [DOI] [PubMed] [Google Scholar]
  12. Eandi M., Zara G. P. Economic impact of resistance in the community. Int J Clin Pract Suppl. 1998 Jun;95:27–38. [PubMed] [Google Scholar]
  13. Einarsson S., Kristjansson M., Kristinsson K. G., Kjartansson G., Jonsson S. Pneumonia caused by penicillin-non-susceptible and penicillin-susceptible pneumococci in adults: a case-control study. Scand J Infect Dis. 1998;30(3):253–256. doi: 10.1080/00365549850160882. [DOI] [PubMed] [Google Scholar]
  14. Feikin D. R., Schuchat A., Kolczak M., Barrett N. L., Harrison L. H., Lefkowitz L., McGeer A., Farley M. M., Vugia D. J., Lexau C. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health. 2000 Feb;90(2):223–229. doi: 10.2105/ajph.90.2.223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Fraise A. P. Guidelines for the control of methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 1998 Sep;42(3):287–289. doi: 10.1093/jac/42.3.287. [DOI] [PubMed] [Google Scholar]
  16. Garbutt J. M., Ventrapragada M., Littenberg B., Mundy L. M. Association between resistance to vancomycin and death in cases of Enterococcus faecium bacteremia. Clin Infect Dis. 2000 Mar;30(3):466–472. doi: 10.1086/313694. [DOI] [PubMed] [Google Scholar]
  17. Gerding D. N., Martone W. J. SHEA conference on antimicrobial resistance. Society for Healthcare Epidemiology of America. Infect Control Hosp Epidemiol. 2000 May;21(5):347–351. doi: 10.1086/501772. [DOI] [PubMed] [Google Scholar]
  18. González C., Rubio M., Romero-Vivas J., González M., Picazo J. J. Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis. 1999 Nov;29(5):1171–1177. doi: 10.1086/313440. [DOI] [PubMed] [Google Scholar]
  19. Gould I. M. A review of the role of antibiotic policies in the control of antibiotic resistance. J Antimicrob Chemother. 1999 Apr;43(4):459–465. doi: 10.1093/jac/43.4.459. [DOI] [PubMed] [Google Scholar]
  20. Harris A. D., Samore M. H., Carmeli Y. Control group selection is an important but neglected issue in studies of antibiotic resistance. Ann Intern Med. 2000 Jul 18;133(2):159–159. doi: 10.7326/0003-4819-133-2-200007180-00018. [DOI] [PubMed] [Google Scholar]
  21. Harthug S., Eide G. E., Langeland N. Nosocomial outbreak of ampicillin resistant Enterococcus faecium: risk factors for infection and fatal outcome. J Hosp Infect. 2000 Jun;45(2):135–144. doi: 10.1053/jhin.2000.0728. [DOI] [PubMed] [Google Scholar]
  22. Ibelings M. M., Bruining H. A. Methicillin-resistant Staphylococcus aureus: acquisition and risk of death in patients in the intensive care unit. Eur J Surg. 1998 Jun;164(6):411–418. doi: 10.1080/110241598750004210. [DOI] [PubMed] [Google Scholar]
  23. Jacoby G. A. Epidemiology of extended-spectrum beta-lactamases. Clin Infect Dis. 1998 Jul;27(1):81–83. doi: 10.1086/514644. [DOI] [PubMed] [Google Scholar]
  24. Lai K. K., Kelley A. L., Melvin Z. S., Belliveau P. P., Fontecchio S. A. Failure to eradicate vancomycin-resistant enterococci in a university hospital and the cost of barrier precautions. Infect Control Hosp Epidemiol. 1998 Sep;19(9):647–652. doi: 10.1086/647892. [DOI] [PubMed] [Google Scholar]
  25. Lavin B. S. Antibiotic cycling and marketing into the 21st century: a perspective from the pharmaceutical industry. Infect Control Hosp Epidemiol. 2000 Jan;21(1 Suppl):S32–S35. doi: 10.1086/503171. [DOI] [PubMed] [Google Scholar]
  26. Lawton R. M., Fridkin S. K., Gaynes R. P., McGowan J. E., Jr Practices to improve antimicrobial use at 47 US hospitals: the status of the 1997 SHEA/IDSA position paper recommendations. Society for Healthcare Epidemiology of America/Infectious Diseases Society of America. Infect Control Hosp Epidemiol. 2000 Apr;21(4):256–259. doi: 10.1086/501754. [DOI] [PubMed] [Google Scholar]
  27. Liss R. H., Batchelor F. R. Economic evaluations of antibiotic use and resistance--a perspective: report of Task Force 6. Rev Infect Dis. 1987 May-Jun;9 (Suppl 3):S297–S312. doi: 10.1093/clinids/9.supplement_3.s297. [DOI] [PubMed] [Google Scholar]
  28. McGowan J. E., Jr Cost and benefit of perioperative antimicrobial prophylaxis: methods for economic analysis. Rev Infect Dis. 1991 Sep-Oct;13 (Suppl 10):S879–S889. doi: 10.1093/clinids/13.supplement_10.s879. [DOI] [PubMed] [Google Scholar]
  29. McGowan J. E., Jr Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance? Infect Control Hosp Epidemiol. 1994 Jul;15(7):478–483. doi: 10.1086/646954. [DOI] [PubMed] [Google Scholar]
  30. Moellering R. C., Jr A novel antimicrobial agent joins the battle against resistant bacteria. Ann Intern Med. 1999 Jan 19;130(2):155–157. doi: 10.7326/0003-4819-130-2-199901190-00012. [DOI] [PubMed] [Google Scholar]
  31. Nathwani D., Malek M. Cost considerations in the evaluation of new therapies for gram-positive bacteria. Int J Antimicrob Agents. 1999 Oct;13(2):71–78. doi: 10.1016/s0924-8579(99)00102-8. [DOI] [PubMed] [Google Scholar]
  32. Neumann P. J., Stone P. W., Chapman R. H., Sandberg E. A., Bell C. M. The quality of reporting in published cost-utility analyses, 1976-1997. Ann Intern Med. 2000 Jun 20;132(12):964–972. doi: 10.7326/0003-4819-132-12-200006200-00007. [DOI] [PubMed] [Google Scholar]
  33. Phelps C. E. Bug/drug resistance. Sometimes less is more. Med Care. 1989 Feb;27(2):194–203. [PubMed] [Google Scholar]
  34. Rennie D., Luft H. S. Pharmacoeconomic analyses: making them transparent, making them credible. JAMA. 2000 Apr 26;283(16):2158–2160. doi: 10.1001/jama.283.16.2158. [DOI] [PubMed] [Google Scholar]
  35. Rubin R. J., Harrington C. A., Poon A., Dietrich K., Greene J. A., Moiduddin A. The economic impact of Staphylococcus aureus infection in New York City hospitals. Emerg Infect Dis. 1999 Jan-Feb;5(1):9–17. doi: 10.3201/eid0501.990102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Schentag J. J. Antibiotic dosing--does one size fit all? JAMA. 1998 Jan 14;279(2):159–160. doi: 10.1001/jama.279.2.159. [DOI] [PubMed] [Google Scholar]
  37. Shlaes D. M., Gerding D. N., John J. F., Jr, Craig W. A., Bornstein D. L., Duncan R. A., Eckman M. R., Farrer W. E., Greene W. H., Lorian V. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol. 1997 Apr;18(4):275–291. doi: 10.1086/647610. [DOI] [PubMed] [Google Scholar]
  38. Soriano A., Martínez J. A., Mensa J., Marco F., Almela M., Moreno-Martínez A., Sánchez F., Muñoz I., Jiménez de Anta M. T., Soriano E. Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. Clin Infect Dis. 2000 Feb;30(2):368–373. doi: 10.1086/313650. [DOI] [PubMed] [Google Scholar]
  39. Vanhems P., Lepape A., Savey A., Jambou P., Fabry J. Nosocomial pulmonary infection by antimicrobial-resistant bacteria of patients hospitalized in intensive care units: risk factors and survival. J Hosp Infect. 2000 Jun;45(2):98–106. doi: 10.1053/jhin.2000.0752. [DOI] [PubMed] [Google Scholar]
  40. Weingarten C. M., Rybak M. J., Jahns B. E., Stevenson J. G., Brown W. J., Levine D. P. Evaluation of Acinetobacter baumannii infection and colonization, and antimicrobial treatment patterns in an urban teaching hospital. Pharmacotherapy. 1999 Sep;19(9):1080–1085. doi: 10.1592/phco.19.13.1080.31597. [DOI] [PubMed] [Google Scholar]
  41. White A. C., Jr, Atmar R. L., Wilson J., Cate T. R., Stager C. E., Greenberg S. B. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis. 1997 Aug;25(2):230–239. doi: 10.1086/514545. [DOI] [PubMed] [Google Scholar]
  42. Wise R., Andrews J. M. Local surveillance of antimicrobial resistance. Synercid Resistance Surveillance Group. Lancet. 1998 Aug 22;352(9128):657–658. doi: 10.1016/s0140-6736(05)79618-5. [DOI] [PubMed] [Google Scholar]

Articles from Emerging Infectious Diseases are provided here courtesy of Centers for Disease Control and Prevention

RESOURCES